Enhancing methotrexate tolerance with folate tagged liposomes in arthritic mice

Journal of Biomedical Nanotechnology

Volumn 11, Issue 12, 2015, Pages 2243-2252

  Nogueira, Eugénia ^a   Lager, Franck ^b,c,d   Le Roux, Delphine ^b,c,d   Nogueira, Patrcia ^e,f   Freitas, Jaime ^e,f   Charvet, Celine ^b,c,d   Renault, Gilles ^b,c,d   Loureiro, Ana ^a   Almeida, Catarina R ^g   Ohradanova Repic, Anna ^h   Machacek, Christian ^h   Bernardes, Gonçalo J L ^i,j   Moreira, Alexandra ^e,f   Stockinger, Hannes ^h   Burnet, Michael ^k   Carmo, Alexandre M ^e,f,l   Gomes, Andreia C ^a   Preto, Ana ^a   Bismuth, Georges ^b,c,d   Cavaco Paulo, Artur ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CNRS   (France)

^e UNIVERSITY OF PORTO   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

^g INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^k Synovo GmbH   (Germany)

^l UNIVERSITY OF PORTO   (Portugal)

more..

Author keywords

Folate Receptor; Liposomes; Macrophages; Methotrexate; Rheumatoid Arthritis

Indexed keywords

COST EFFECTIVENESS; LIPOSOMES; MACROPHAGES; MAMMALS; PATIENT TREATMENT;

ACTIVATED MACROPHAGES; BIOLOGICAL THERAPIES; COLLAGEN-INDUCED ARTHRITIS; FOLATE RECEPTOR; HYDROPHOBIC FRAGMENTS; LIPOSOMAL FORMULATION; METHOTREXATE; RHEUMATOID ARTHRITIS;

DISEASES;

5' NUCLEOTIDASE; CD11B ANTIGEN; CD39 ANTIGEN; FOLATE RECEPTOR 2; FOLIC ACID; LIPOSOME; METHOTREXATE; FOLATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CELL SUBPOPULATION; CELL SURFACE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERANCE; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; RHEUMATOID ARTHRITIS; ANIMAL; ARTHRITIS, RHEUMATOID; CELL LINE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; MALE; METABOLISM;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL LINE; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; GENE EXPRESSION REGULATION; HUMANS; LIPOSOMES; MACROPHAGES; MALE; METHOTREXATE; MICE;

EID: 84941551653     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2170     Document Type: Article

References (38)

1. G. S. Firestein, Evolving concepts of rheumatoid arthritis. Nature 423, 356 (2003).
2. J. Presumey, G. Courties, P. Louis-Plence, V. Escriou, D. Scherman, Y. M. Pers, H. Yssel, J. Pene, D. Kyburz, S. Gay, C. Jorgensen, and F. Apparailly, Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis. Ann. Rheum. Dis. 72, 1717 (2013).
3. F. M. Brennan and I. B. McInnes, Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest. 118, 3537 (2008).
4. J. S. Smolen, R. Landewé, F. C. Breedveld, M. Buch, G. Burmester, M. Dougados, P. Emery, C. Gaujoux-Viala, L. Gossec, J. Nam, S. Ramiro, K. Winthrop, M. de Wit, D. Aletaha, N. Betteridge, J. W. J. Bijlsma, M. Boers, F. Buttgereit, B. Combe, M. Cutolo, N. Damjanov, J. M. W. Hazes, M. Kouloumas, T. K. Kvien, X. Mariette, K. Pavelka, P. L. C. M. van Riel, A. Rubbert-Roth, M. Scholte-Voshaar, D. L. Scott, T. Sokka-Isler, J. B. Wong, and D. van der Heijde, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492 (2013).
5. L. D. Quan, G. M. Thiele, J. Tian, and D. Wang, The development of novel therapies for rheumatoid arthritis. Expert Opin. Ther. Pat. 18, 723 (2008).
6. M. Bulatovíc, M. W. Heijstek, M. Verkaaik, E. H. P. van Dijkhuizen, W. Armbrust, E. P. A. Hoppenreijs, S. Kamphuis, W. Kuis, T. C. G. Egberts, G. Sinnema, C. M. A. Rademaker, and N. M. Wulffraat, High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: Development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 63, 2007 (2011).
7. I. Colmegna, B. R. Ohata, and H. A. Menard, Current understanding of rheumatoid arthritis therapy. Clin. Pharmacol. Ther. 91, 607 (2012).
8. J. M. Kremer, G. S. Alarcón, R. W. Lightfoot, R. F. Willkens, D. E. Furst, H. J. Williams, P. B. Dent, and M. E. Weinblatt, Methotrexate for rheumatoid arthritis. Arthritis Rheum. 37, 316 (1994).
9. S. Merkesdal, J. Ruof, T. Mittendorf, and H. Zeidler, Costeffectiveness of TNF-blocking agents in the treatment of rheumatoid arthritis. Expert. Opin. Pharmacother. 5, 1881 (2004).
10. E. Nogueira, I. C. Mangialavori, A. Loureiro, N. G. Azoia, M. P. Sárria, J. Härmark, U. Shimanovich, A. Rollett, G. J. L. Bernardes, G. Guebitz, H. Hebert, J. P. F. C. Rossi, A. C. Gomes, A. Preto, and A. Cavaco-Paulo, Folate-tailed peptide from surfactant protein D enhances liposome drug delivery. (2015), submitted.
11. C. M. Paulos, M. J. Turk, G. J. Breur, and P. S. Low, Folate receptormediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv. Drug Deliv. Rev. 56, 1205 (2004).
12. I.-M. Jou, C.-F. Lin, K.-J. Tsai, and S.-J. Wei, Macrophage-mediated inflammatory disorders. Mediators Inflamm. 2013, 3 (2013).
13. B. Varghese, N. Haase, and P. S. Low, Depletion of folatereceptor-positive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus. Mol. Pharm. 4, 679 (2007).
14. P. S. Low, W. A. Henne, and D. D. Doorneweerd, Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 41, 120 (2007).
15. T. Nagai, M. Tanaka, Y. Tsuneyoshi, B. Xu, S. Michie, K. Hasui, H. Hirano, K. Arita, and T. Matsuyama, Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor. Cancer Immunol. Immunother. 58, 1577 (2009).
16. J. S. Courtenay, M. J. Dallman, A. D. Dayan, A. Martin, and B. Mosedale, Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283, 666 (1980).
17. N. Saidenberg-Kermanac'h, N. Bessis, D. Lemeiter, M. C. de Vernejoul, M. C. Boissier, and M. Cohen-Solal, Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. J. Clin. Immunol. 24, 370 (2004).
18. G. Clavel, C. Marchiol-Fournigault, G. Renault, M.-C. Boissier, D. Fradelizi, and N. Bessis, Ultrasound and Doppler micro-imaging in a model of rheumatoid arthritis in mice. Ann. Rheum. Dis. 67, 1765 (2008).
19. A. Puig-Kröger, E. Sierra-Filardi, A. Domínguez-Soto, R. Samaniego, M. T. Corcuera, F. Gómez-Aguado, M. Ratnam, P. Sánchez-Mateos, and A. L. Corbí, Folate receptor-is expressedby tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 69, 9395 (2009).
20. J. W. Van Der Heijden, R. Oerlemans, B. A. C. Dijkmans, H. Qi, C. J. V. D. Laken, W. F. Lems, A. L. Jackman, M. C. Kraan, P. P. Tak, M. Ratnam, and G. Jansen, Folate receptor-as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum. 60, 12 (2009).
21. E. Nogueira, A. Loureiro, P. Nogueira, J. Freitas, C. R. Almeida, J. Harmark, H. Hebert, A. Moreira, A. M. Carmo, A. Preto, A. C. Gomes, and A. Cavaco-Paulo, Liposome and protein based stealth nanoparticles. Faraday Discuss 166, 417 (2013).
22. A. L. de Barros, L. Mota, D. C. Soares, C. M. de Souza, G. D. Cassali, M. C. Oliveira, and V. N. Cardoso, Long-circulating, pHsensitive liposomes versus long-circulating, non-pH-sensitive liposomes as a delivery system for tumor identification. J. Biomed. Nanotechnol. 9, 1636 (2013).
23. B. Csóka, Z. Selmeczy, B. Koscsó, Z. H. Németh, P. Pacher, P. J. Murray, D. Kepka-Lenhart, S. M. Morris, W. C. Gause, S. J. Leibovich, and G. Haskó, Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J. 26, 376 (2012).
24. L. Antonioli, P. Pacher, E. S. Vizi, and G. Hasko, CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 19, 355 (2013).
25. W. Xia, A. R. Hilgenbrink, E. L. Matteson, M. B. Lockwood, J. X. Cheng, and P. S. Low, A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 113, 438 (2009).
26. Y. Feng, J. Shen, E. D. Streaker, M. Lockwood, Z. Zhu, P. S. Low, and D. S. Dimitrov, A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity. Arthritis Res. Ther. 13, 1 (2011).
27. R. Nagayoshi, T. Nagai, K. Matsushita, K. Sato, N. Sunahara, T. Matsuda, T. Nakamura, S. Komiya, M. Onda, and T. Matsuyama, Effectiveness of anti-folate receptor beta antibody conjugated with truncated pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages. Arthritis Rheum. 52, 2666 (2005).
28. C. M. Paulos, B. Varghese, W. R. Widmer, G. J. Breur, E. Vlashi, and P. S. Low, Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res. Ther. 8, 28 (2006).
29. Y. S. Yi, W. Ayala-Lopez, S. A. Kularatne, and P. S. Low, Folatetargeted hapten immunotherapy of adjuvant-induced arthritis: Comparison of hapten potencies. Mol. Pharm. 6, 1228 (2009).
30. J. W. van der Heijden, R. Oerlemans, B. A. Dijkmans, H. Qi, C. J. van der Laken, W. F. Lems, A. L. Jackman, M. C. Kraan, P. P. Tak, M. Ratnam, and G. Jansen, Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum. 60, 12 (2009).
31. Y. Y. Gent, K. Weijers, C. F. Molthoff, A. D. Windhorst, M. C. Huisman, D. E. Smith, S. A. Kularatne, G. Jansen, P. S. Low, A. A. Lammertsma, and C. J. van der Laken, Evaluation of the novel folate receptor ligand [18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. Arthritis Res. Ther. 15, 1 (2013).
32. E. L. Matteson, V. J. Lowe, F. G. Prendergast, C. S. Crowson, K. G. Moder, D. E. Morgenstern, R. A. Messmann, and P. S. Low, Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin. Exp. Rheumatol. 27, 253 (2009).
33. T. P. Thomas, S. N. Goonewardena, I. J. Majoros, A. Kotlyar, Z. Cao, P. R. Leroueil, and J. R. Baker, Jr., Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum. 63, 2671 (2011).
34. M. Li, H. Deng, H. Peng, and Q. Wang, Functional nanoparticles in targeting glioma diagnosis and therapies. J. Nanosci. Nanotechnol. 14, 415 (2014).
35. F. Jia, X. Liu, L. Li, S. Mallapragada, B. Narasimhan, and Q. Wang, Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J. Control. Release 172, 1020 (2013).
36. R. M. Lopes, M. M. Gaspar, J. Pereira, C. V. Eleutério, M. Carvalheiro, A. J. Almeida, and M. E. M. Cruz, Liposomes versus lipid nanoparticles: Comparative study of lipid-based systems as oryzalin carriers for the treatment of leishmaniasis. J. Biomed. Nanotechnol. 10, 3647 (2014).
37. W. Yuan, R. Kuai, R. Ran, L. Fu, Y. Yang, Y. Qin, Y. Liu, J. Tang, H. Fu, Q. Zhang, M. Yuan, Z. Zhang, F. Gao, and Q. He, Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: In vitro and in vivo study. J. Biomed. Nanotechnol. 10, 1563 (2014).
38. M. Liu, M. Li, G. Wang, X. Liu, D. Liu, H. Peng, and Q. Wang, Heart-targeted nanoscale drug delivery systems. J. Biomed. Nanotechnol. 10, 2038 (2014).